九典制药(300705) - 300705九典制药投资者关系管理信息20260313

Group 1: Brand Development - The company is expanding its brand presence by targeting retail pharmacies and online platforms while reinforcing its hospital market [2] - A brand upgrade event was held on December 6, 2025, introducing the "Mr. Pain Relief" branding to enhance market competitiveness [2] - The new slogan "For pain relief, choose Jiudian" aims to address consumer pain points and improve brand recognition [2] Group 2: Financial Performance and Market Strategy - The implementation of centralized procurement for the Loxoprofen Sodium Gel Patch may lead to a temporary decline in gross margin due to price adjustments [3] - In 2026, the company plans to stabilize existing business while driving innovation, focusing on both hospital and retail markets [3] - The company has 18 products eligible for continued procurement under national centralized purchasing agreements, which will support sales and market expansion [3] Group 3: Product Development and Innovation - The JIJ02 gel is expected to complete Phase I clinical trials in the first half of 2026 and initiate Phase II trials [4] - The company has established a clear and competitive matrix of external products, including Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, with significant advantages in exclusivity and insurance coverage [4] - The company aims to enhance its product offerings to meet diverse clinical and consumer needs, particularly in the traditional plaster market [4] Group 4: Employee Incentives and Corporate Governance - The completed share repurchase plan will primarily be used for employee stock incentives to align interests between the company, shareholders, and core team [4] - Future stock incentive plans will be developed based on market conditions and strategic planning to motivate employees and foster talent [4]